Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials group 128)

Journal of Infectious Diseases

Volumn 173, Issue 5, 1996, Pages 1097-1106

  Brady, Michael T ^a   McGrath, Nuala ^b   Brouwers, Pim ^b   Gelber, Richard ^b   Fowler, Mary Glenn ^b   Yogev, Ram ^b   Hutton, Nancy ^b   Bryson, Yvonne J ^b   Mitchell, Charles D ^b   Fikrig, Senih ^b   Borkowsky, William ^b   Jimenez, Eleanor ^b   McSherry, George ^b   Rubinstein, Arye ^b   Wilfert, Catherine M ^b   McIntosh, Kenneth ^b   Elkins, Mary Maha ^b   Weintrub, Peggy S ^b  

^a Section of Infectious Diseases   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 8944262046     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.5.1097     Document Type: Article

References (13)

1. McKinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991;324:1018-25.
2. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-96.
3. Brouwers P, Moss H, Wolters P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990;117:980-5.
4. McKinney RE, Pizzo PA, Scott GB, et al. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. J Pediatr 1990;116:640-7.
5. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency viras type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727-37.
6. Kline MW, Shearer WT. A national survey on the care of infants and children with human immunodeficiency virus infection. J Pediatr 1991;118:817-21.
7. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990;323:1015-21.
8. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009-14.
9. Epstein LG, Sharer LR, Oleske JM, et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 1989;78:678-87.
10. Belman AL, Diamond G, Dickson D, et al. Pediatric acquired immunodeficiency syndrome: neurologie syndromes. Am J Dis Child 1988;149:29-35.
11. Ultmann MH, Belman L, Ruff HA. Developmental abnormalities in infants and children with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Dev Med Child Neurol 1985;27:563-71.
12. Belman AI, Ultmann MH, Horopian DS, et al. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann Neurol 1985;18:560-6.
13. Wechsler D. Manual for the Wechsler intelligence scale for children-revised. San Antonio, TX: Psychological Corp., 1974.